Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Altimmune

Aytu BioScience

Clorox

Co-Diagnostics

Quest Diagnostics

Gilead Sciences

Inovio Pharmaceuticals

Lakeland Industries

NanoViricides

Zoom Video

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

How Coronavirus Stocks Were Holding Up in Monday’s Sell-Off

Biogen

BioMarin Pharmaceutical

Emergent BioSolutions

Momenta Pharmaceuticals

Mylan

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

Why These Drug Stocks Soared Today

AbbVie

Moderna

Vir Biotechnology

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Biotech Sector in Focus as Coronavirus Spreads Panic

Markets were crushed again on Thursday after President Trump announced a travel ban to Europe on Wednesday night.

How Coronavirus Stocks Responded to Thursday’s Sell-Off

The clinical-stage biotech had a busy fourth quarter and even busier start to 2020.

Novavax's Q4 Update: Good News, Bad News, and Great News

Novavax's (NVAX) CEO Stan Erck on Q4 2019 Results - Earnings Call Transcript

Novavax (NVAX) delivered earnings and revenue surprises of -4.63% and 120.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates

Novavax (NVAX) earnings for the vaccine company's fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday.

Novavax Earnings: NVAX Stock Soars 8% on Strong Q4 Revenue Beat

Regeneron Pharmaceuticals

COVID-19 has rocked markets and caused panic across the world. While investors are feeling the pain as global supply chains may become constricted, playing on COVID-19 stocks has proven very lucrative.

Coronavirus Stocks See Rising Tide in Short Interest

GAITHERSBURG, Md., March  11, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) today announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017. Matrix-M is a key component in the malaria vaccine candidate, currently in a Phase 2b clinical trial sponsored by the Jenner Institute, with top-line data expected to be reported in the second quarter of 2020.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Cocrystal Pharma

GlaxoSmithKline

Johnson & Johnson

Pfizer

Sanofi

Vaxart

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Novavax's attempt to develop a vaccine for COVID-19 just got a helping hand.

Novavax Receives $4 Million in Funding to Develop a Vaccine for COVID-19

Shares of Novavax Inc. NVAX, +9.28% were up 8% in trading on Tuesday after the company said it had received $4 million from the Coalition for Epidemic Preparedness (CEPI) to develop a COVID-19 vaccine.

Novavax stock rises on funding for COVID-19 vaccine trial

Novavax lands a $4 billion grant to develop its COVID-19 vaccine candidate.

Why Novavax (NVAX) Stock Is Skyrocketing  Today

GAITHERSBURG, Md., March  10, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI and Novavax are having ongoing discussions on additional funding from CEPI to address Novavax’ costs through Phase 1.

Novavax Awarded Funding from CEPI  for COVID-19 Vaccine Development

AIM ImmunoTech Inc

Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.

Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …

AnaptysBio

A pair of black swans crushed these three healthcare stocks today.

Why AnaptysBio, Co-Diagnostics, and Novavax Are Getting Crushed Today

These two biotechs are leaders in the race to develop a coronavirus vaccine. Which stock is the better pick for investors?

Better Coronavirus Stock: Inovio Pharmaceuticals vs. Novavax

Despite its attempt to develop a vaccine for COVID-19, Novavax's prospects aren't particularly attractive.

Amid the Coronavirus Frenzy, Novavax Remains a Risky Bet

Investors bet on Novavax’s coronavirus vaccine program.

Why Novavax Shares Rose 110% in February

Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.

5 Drug Makers to Gain From Coronavirus Outbreak

Inovio's accelerated timeline for its coronavirus vaccine program is shaking things up for three biotech stocks.

Why Inovio Shares Are Soaring Today While Moderna and Novavax Shares Are Sinking

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

Alpha Pro Tech

Why Novavax, Lakeland Industries, and Alpha Pro Tech Are Crashing Today

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

News for Novavax Stock (NVAX)